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Abstract
More than 50% of children with severe 46,XY disorders of sex development (DSD) do not have a definitive etiological
diagnosis. Besides gonadal dysgenesis, defects in androgen biosynthesis, and abnormalities in androgen sensitivity, the
Mastermind-like domain containing 1 (MAMLD1) gene, which was identified as critical for the development of male
genitalia, may be implicated. The present study investigated whether MAMLD1 is implicated in cases of severe 46,XY DSD
and whether routine sequencing of MAMLD1 should be performed in these patients. Seventy children with severe non-
syndromic 46,XY DSD of unknown etiology were studied. One hundred and fifty healthy individuals were included as
controls. Direct sequencing of the MAMLD1, AR, SRD5A2 and NR5A1 genes was performed. The transactivation function of
the variant MAMLD1 proteins was quantified by the luciferase method. Two new mutations were identified: p.S143X
(c.428C.A) in a patient with scrotal hypospadias with microphallus and p.P384L (c.1151C.T) in a patient with penile
hypospadias with microphallus. The in vitro functional study confirmed no residual transactivating function of the p.S143X
mutant and a significantly reduced transactivation function of the p.P384L protein (p=0.0032). The p.P359S, p.N662S and
p.H347Q variants are also reported with particularly high frequency of the p.359T- p.662G haplotype in the DSD
patients. Severe undervirilization in XY newborns can reveal mutations of MAMLD1. MAMLD1 should be routinely
sequenced in these patients with otherwise normal AR, SRD5A2 and NR5A1genes.
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Introduction
The disorders of sex development (DSD) comprise a variety of
anomalies defined by congenital conditions in which chromosom-
al, gonadal, or anatomical sex is atypical. The prevalence of the
46,XY disorders of sex development (46,XY DSD) is difficult to
determine with accuracy because of the heterogeneity in the
clinical presentation and the etiologies. The estimated incidence of
severe 46,XY DSD with uncertain sex is 2.2 per 10,000 births [1],
and for a minor form of 46,XY DSD with isolated and non-severe
hypospadias, the incidence is estimated at 1 in 250–400 births [2].
Two independent surveillance systems in the United States, the
nationwide Birth Defects Monitoring Program (BDMP) and the
Metropolitan Atlanta Congenital Defects Program (MACDP),
reported a near doubling in the hypospadias rate in comparison
with the immediately preceding decades [3]. Although recent
studies have questioned this reported rise and provide conflicting
data [4,5], the elucidation of the pathophysiology of these genital
malformations remains challenging.
The etiologies of 46,XY DSD are usually gonadal dysgenesis
(defect in SRY and downstream genes such as SOX9, WT1, NR5A1
[6,7], etc.), defects in androgen biosynthesis and, more frequently,
abnormalities in androgen sensitivity. Unfortunately, more than
50% of children with severe 46,XY DSD presenting with
uncertain sex do not have a definitive clinical diagnosis [8]. For
instance, an AR gene defect is identified in less than 10% of the
cases [9].
In addition to these well classified causes, a recent candidate
gene was identified as critical for the development of male
genitalia: the Mastermind-like domain containing 1 (MAMLD1)
gene (formerly CXorf6). This gene was discovered during studies to
find the gene responsible for X-linked myotubular myopathy,
MTM1, which maps to proximal Xq28 [10]: MAMLD1 was
observed to be deleted in patients with both the myopathy and
external genital malformations [10,11,12]. Polymorphisms of
MAMLD1 have been reported in patients with isolated hypospa-
dias, the less severe form of 46,XY DSD, but these variants usually
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32505do not affect the transactivation of the protein [13,14]. Conversely,
severe 46,XY DSD with uncertain sex has been sparsely studied.
To date, only one study has focused on these patients: Fukami
et al. identified three nonsense mutations in four individuals from a
group of 166 patients [15]. The aim of the present study was to
determine whether MAMLD1 is frequently implicated in newborns
and children with severe 46,XY DSD with uncertain sex and
whether MAMLD1 should be routinely sequenced in these
patients.
Materials and Methods
Patients and controls
Two hundred and twenty individuals were included in this study.
Seventy children presented with non-syndromic 46,XY DSD of
unknown etiology. According to the Quigley classification [16], 8
patients exhibited a stage 2 phenotype; 32 patients, stage 3; 20
patients, stage 4; 5 patients, stage 5; and 5 patients, stage 6. One
hundred and fifty healthy individuals were included as controls.
Controls were chosen among patients without urinary, genital, or
endocrine disease, or any other congenital malformation. For
instance, patients with acute appendicitis or operated on for
circumcision without phimosis were included. This study was
approved by the Institutional Review Board (CPP-Montpellier, ID
RCB No. 2008-A00781-54). Written consent was obtained from the
parents, carers or guardians on behalf of the participating minors.
When a mutation was identified, other family members were
examined if possible. The patients and controls were Caucasian.
DNA extraction
DNA was extracted from peripheral blood using a QIAamp
DNA blood minikit (Qiagen, Courtaboeuf, France).
Mutational analysis of MAMLD1
Direct sequencing of MAMLD1 coding exons and their flanking
splice sites was performed in all patients and controls using primers
as previously described [17]. The 3730xl DNA Analyzer (Applied
Biosystems, Foster City, CA, USA) was used. Sequencing reactions
were repeated twice with at least two different PCR products. The
DNA sequences were compared with the sequences of normal
controls and the reference genomes from the ensembl.org database
(Ensembl: ENSG00000013619) and the genebank database (MIM:
300120, NCBI Gene ID: 10046). It is notable that the number of
the cDNA and amino acids has been changed recently because of
the recognition of a novel MAMLD1 start codon. This report
describes MAMLD1 cDNA and amino acids according to the new
system.
Molecular analysis of androgen sensitivity
A molecular analysis of the androgen receptor (AR) and 5 alpha
reductase type 2 (SRD5A2) genes was performed in all patients.
Figure 1. Electrochromatograms and pedigrees of the three patients with MAMLD1 mutations. The black squares indicate patients with
posterior hypospadias. All mutant sequences were controlled by wildtype (WT) DNA. Regarding case 1’s family, only the members III-3 and II-4 were
genotyped, as the other members in the pedigree declined genetic testing.
doi:10.1371/journal.pone.0032505.g001
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primers and reactions previously described [18]. Molecular
analysis of the SRD5A2 gene (exons 1–5) was performed as
previously reported [19]. PCRs were verified for correct length on
agarose gel, purified with Qiaquick PCR columns (Qiagen), and
sequenced with the ABI Prism Big Dye terminator sequencing kit.
NR5A1was sequenced in 46,XY DSD children with low plasma
testosterone as previously published [6,20].
Homology study
Ensembl.org detected the putative homologs of the human
MAMLD1 gene and alignments were made with the ClustalW
software at http://www.ebi.ac.uk/Tools/msa/clustalw2/.
Structure prediction
The potential impact of variants was first predicted using X in-
silico tools for secondary structure, tertiary structure and prediction
of the consequences of amino acid changes.
The secondary structure for wildtype and variants was predicted
using JPred software [21] (http://www.compbio.dundee.ac.uk/
www-jpred/). The relative accessibility of amino acids was studied
with Netsurf software [22] (http://www.cbs.dtu.dk/services/
NetSurfP/). The three-dimensional structure was predicted by
the Protein Homology/analogY Recognition Engine (PhyreEn-
gine) from the Structural Bioinformatics Group, Imperial College,
London, at http:www.sbg.bio.ic.ac.uk/phyrew/. This tool can
detect remote homologous proteins with similar tertiary structures,
based on multiple sequence profiles with structure-based profiles
[23].
The functional consequences of amino acid changes were
predicted using four algorithms. Polyphen (Harvard, USA) [24,25],
Panther [26], Sift (University of British Columbia) [27] and SNP-3D
(University of Maryland) [28] were used, respectively, at http://
genetics.bwh.harvard.edu/pph/, http://www.pantherdb.org/tools/
csnpScoreForm.jsp., http://sift.jcvi.org/, and http://www.snps3d.
org/modules.php?name=Search&op=advanced%20search. These
algorithms are based on the alignment of orthologous and/or
paralogous protein sequences and/or structural constraints.
Transactivation analysis of MAMLD1
The transactivation function of the variant MAMLD1 proteins
was analyzed by the luciferase method [29]. We used the
previously reported luciferase reporter vector containing the
promoter sequence of mouse hairy/enhancer of split 3 (Hes3)
(–2,715,+261 bp) [30] and expression vectors containing cDNAs
for wildtype MAMLD1, p.S143X and p.P384L [29]. Mouse Leydig
tumor (MLTC1) cells (ATCC, CRL-2065) seeded in 12-well dishes
(0.5–1.0610
5 cells/well) were transiently transfected using Lipo-
fectamine 2000 (Invitrogen) with 0.6 mg of luciferase reporter
vector and 0.6 mg of expression vector for wildtype or variant
MAMLD1, together with 20 ng of pRL-CMV vector (Promega)
used as an internal control. As a control for the expression vectors,
an empty counterpart vector was transfected. Luciferase assays
performed with a Lumat LB9507 (Berthold) 48 hours after
transfection were repeated three times.
Table 1. Clinical and hormonal data of patients with mutated MAMLD1.
Patient Case 1 Case 2
MAMLD1 mutation pS143X pP384L
Previous medical history None Maternal diabetes
Genital phenotype
Urethral meatus Scrotal Penile posterior
Age at exam (yr,mo) 0,0 0,0
Microphallus Yes, 20 mm Yes, 20 mm with cuvature
Testis position Intra-scrotal Intra-scrotal
Testis size (normal=1–2 ml) Normal Normal
Scrotal appearance Ventral transposition, Bifid Scrotum Bifid Scrotum
Renal and urinary tract structure Normal Normal
Extragenital phenotype Normal Normal
Growth
Birth height, cm (SDS) 51 (+0) 50.5 (+0)
Birth weight, Kg (SDS) 3.540 (+0) 3.750 (+0.5)
Serum hormone level
Time of measurment (yr,mo) 0,0 0,3
Testosterone (ng/ml) (1–3 ng/ml) 1.78 ,0.07
LH (UI/l) (1–12 UI/l) 10 0.3
FSH (UI/l) (1–10 UI/l) 0.8 0.8
AMH 336 ng/ml 19 ng/ml*
Inhibin NA ,15 ng/ml*
SD: standard deviation. ND: not determined. NA: not available. DHT: dihydrotestosterone. DHEA: dihydroepiandrsosterone. Parentheses indicate the standard deviation
for height and weight and the normal range for hormone serum levels. Testes of 1–2 ml can be regarded as normal, as recently reported by Shibata et al. [34].
*It is notable that anti-mullerian hormone and inhibin were lowered in one case. MAMLD1 is indeed reported to be expressed in Sertoli cells, as well [15].
doi:10.1371/journal.pone.0032505.t001
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Haplotype frequencies were compared between cases and
controls using the x
2 test and the Fisher test on SPSS 16.0 software.
The odds ratio (OR) was also considered with the logit confidence
intervals method: OR{CI~e
LN(OR)+1:96 1
Az1
Bz1
Cz1
D ðÞ
0:5
. Hapmap
and ensembl.org were used to exclude linkage disequilibrium.
Regarding the transactivation analysis of MAMLD1, the results are
expressed using the mean and SD, and statistical significance was
determined by the t-test.
Results
Mutations of MAMLD1 and functional analyses
Among the 70 newborns and children with 46,XY DSD, two
new mutations were identified in two unrelated patients: p.S143X
(c.428C.A) and p.P384L (c.1151C.T) (Fig. 1). The clinical and
genetic data are summarized in Table 1. None of these mutations
was noted in the control group. The sequences of the AR, SRD5A2
and NR5A1 genes were normal in these patients.
a- The p.S143X mutation was predicted to cause a short and
truncated protein. The in silico prediction showed profoundly
modified amino acid accessibility and 3D structure. Relative
surface accessibility and absolute surface accessibility of the last
amino acid changed from 0.248 to 0.834 and from 29.124 to
97.721, respectively. PhyreEngine predicted the loss of any
functional site without a residual consensus sequence (no
homologous sequence over 5% through whole genome) (Fig. 2).
The in vitro functional study confirmed no residual transactivating
function of the mutant (Fig. 3). Interestingly, a maternal uncle and
a maternal cousin of the index case both exhibited severe
hypospadias (not available for genetic testing). The mother was
indeed heterozygous for the mutation (Fig. 1).
b- The p.P384L mutation was found in a patient with posterior
penile hypospadias and microphallus. No cryptrochidism was
noted. The secondary structure was predicted to be changed in the
next four amino acids. The relative and absolute accessibilities of
the amino acid were modified from 0.27 to 0.35 and from 39.07 to
65.25, respectively. The 3D structure prediction of the mutated
protein was significantly changed (Fig. 2). All four in silico
Figure 2. Tertiary structure prediction of the wildtype protein (left column) and with the mutants. 3D structure was predicted at Protein
Homology/analogY Recognition Engine (PhyreEngine) from the Structural Bioinformatics Group, Imperial College, London, at http:www.sbg.bio.ic.ac.
uk/phyre,/. The plain arrows show the changes in the shape of the protein between the wildtype and p.P384L.
doi:10.1371/journal.pone.0032505.g002
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conserved amino acid throughout species (Table 3). Functional
studies confirmed the significantly reduced transactivation func-
tion of the p.P384L protein with 60% residual activity when
compared with the wildtype protein, p=0.0032 (Fig. 3).
Polymorphisms of MAMLD1
We identified three polymorphisms of MAMLD1 in our series:
p.P359S (c.1075C.T, rs41313406), p.N662S (c.1985A.G,
rs2073043) and p.H347Q (c.1041C.A, rs62641609). Regarding
the p.P359S and p.N662S polymorphisms, 14 patients exhibited
double polymorphisms (S-S haplotype) and five had the p.N359S
polymorphism. The phenotypes of the patients with the S-S
haplotype were as follows: penile posterior hypospadias and
cryptorchidism in three cases, hypospadias and microphallus in
five cases (anterior n=1, penile posterior n=2 and scrotal
hypospadias n=2), and cryptorchidism and microphallus in six
cases (bilateral cryptorchidism n=5, unilateral cryptorchidism
n=1). Using hapmap and ensembl.org, no linkage disequilibrium
was found for these two variants. In previous studies, we and
others found that the S-S haplotype was present in only 6/150
controls (4.0%) and 23/360 controls (6.4%) [13,14]. By combining
the published series for controls (matched patients and controls),
we determined that the incidence of the S-S haplotype was higher
in the DSD patients (20%, n=70 vs. 6%, n=510, p=0.0003)
(OR=3.86, CI from 1.94 to 7.70, p=0.05). Haplotypes and their
relative frequencies in each group of patients are summarized in
Table 4.
The p.H347Q variant, previously reported as a polymorphism
especially in sub-Saharan populations (rs62641609, http://www.
ensembl.org/Homo_sapiens/Variation/Summary?r=X:149638386-
149639386;v=rs62641609;vdb=variation;vf=16740729), was identi-
fied in a patient with posterior hypospadias and microphallus (25 mm
length at birth).
Discussion
MAMLD1 is a good candidate to explore in patients with
unexplained 46,XY DSD, as it has been shown to be expressed in
fetal Leydig cells around the critical period for sex development
[15]. The transient knockdown of MAMLD1 mRNA expression
results in significantly reduced testosterone production in mouse
Leydig tumor cells [29]. MAMLD1 is further coexpressed with
steroidogenic factor (NR5A1), which regulates the transcription of
genes involved in sex development, and an NR5A1target site was
found within the MAMLD1 gene [29,31]. MAMLD1 thus seems to
have an important role in modulating testosterone production
during sex development and is involved in the 46,XY disorders of
sex development [32].
Regarding the minor forms of 46,XY DSD with isolated and
non-severe hypospadias, mutational studies of MAMLD1 have
identified several polymorphisms in this gene. We reported the
following variants in patients with isolated hypospadias: p.P359S,
p.V505A, p.N662S and p.604ins3Q [13,17], all of which were
recently confirmed as polymorphisms [14]. The p.Q602K
mutation was also found in one patient with posterior hypospadias
and was predicted to affect the splicing process. An association
between isolated hypospadias and the rare haplotype p.P359S-
p.N662S is also suspected [13,14].
Figure 3. Transactivation function of the variants of the
MAMLD1 protein analyzed by the luciferase method. The
activity is evaluated for pHes3-luc vector.
doi:10.1371/journal.pone.0032505.g003
Table 2. Prediction of affected protein function using four
algorithms.
Algorithm pP384L
Polyphen Probably damaging
score=0.961 (sensitivity: 0.71; specificity: 0.93)
Sift Affect protein function
Sift score=0.04
Panther Probability of deleterious effect=0.42
(subPSEC score=22.7)
SNPS3D Deleterious
(svm score=21.75)
References and online access are indicated in the text. Mathematical calculation
of the significance of each score is available online.
doi:10.1371/journal.pone.0032505.t002
Table 3. Homology study showed that this amino acid was
highly conserved through species for the c.1041C.A and
c.1151C.T mutations.
Patient MSSNTLSGSTLRGSLNALLSSMTSSSNAAL
Human-MAMLD1 MSSNTLSGSTLRGSPNALLSSMTSSSNAAL
Pig MSSSSLPGSTLHGSPGALLSSGAPSSSSAL
Horse MSSSNLPGSTLQGSPNALLSSMVSGSSAAL
Chimpanzee MSSNTLSGSTLRGSPNALLSSMTSSSNAAL
Mouse MSSSSLSGSAVQSSPNALLSSMAPSSNASL
Rabbit MAPHSLPGSSLQGSPNALLSSMAPNSSGAL
Dog MASSNLPGSSFQASPNALLASMASASSAGL
Cat MASGNLPGSAFQGSPNALLASMASGSSAAL
doi:10.1371/journal.pone.0032505.t003
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published paper to date has reported three MAMLD1 mutations
(p.E124X, p.Q197X and p.R653X) [15]. It is precisely in this
situation of severe genital malformation that the diagnosis of the
causative mechanism is of clinical interest for medical treatment
(hormone substitution, pubertal follow-up). In order to determine
whether this report was an exceptional observation or of practical
clinical interest, we screened 70 patients with severe 46,XY DSD
of unknown origin. We identified two new mutations of MAMLD1
in patients with severe hypospadias and microphallus (1 stop
codon and 1 missense mutation). These mutations were associated
with a severe phenotype, and reduced (p.P384L) or abolished
(p.S143X) transactivation function was found in two cases. 46,XY
DSD with normal AR, SRD5A2 and NR5A1gene sequences can
thus reveal a mutation of MAMLD1. This finding suggests a new
diagnostic investigation for these patients and may be helpful in
genetic counselling if a mutation is identified. It also provides new
insight into the pathophysiology of DSD. Indeed, in the family of
the child bearing the p.S143X mutation, the mother was
heterozygous and two other males on the maternal side of the
family exhibited a consistent phenotype. Unfortunately, the family
declined any further investigation.
The mechanisms by which these mutations with reduced
transactivation induce DSD are still under investigation. As noted
above, several studies have provided strong evidence of MAMLD1
implication in fetal sex development through modulation of
testosterone production at the time of sex differentiation. The
plasma testosterone measured in one of our cases was indeed
lowered but it was normal in the other one, as previously reported
in patients with nonsense mutations [15]. Plasma testosterone
evaluation is thus not systematically helpful in orienting the
diagnosis of DSD since mutations of the genes implicated in
testosterone production - such as MAMLD1 and NR5A1 - have
been reported in 46,XY DSD patients with normal plasma
testosterone. These findings, along with the absence of correlation
between the in vitro functional analysis and the biological and
clinical phenotype, suggest that the genital malformation is
primarily related to a transient prenatal testicular (Leydig cell)
dysfunction and the resulting compromised testosterone produc-
tion around the critical period of sex differentiation [33]. In the
postnatal period, the mouse homolog of MAMLD1 was indeed
reported to be weakly expressed in the testis at one week of age
and the expression was faint thereafter.
We also report a high incidence of the rare haplotype p.P359S-
p.N662S in our series. The p.P359S (which was designated
p.P286S in the previous report) variant was first reported in a
patient with hypospadias but it was absent in his brother and
nephew with the same phenotype [15]. The p.N662S (which was
designated p.P589S in the previous report) variant was found in
hypospadiac patients but was also reported in a normal
population, although with low incidence [15]. We and others
have found that the S-S haplotype is associated with a minor form
of DSD, i.e., isolated hypospadias [14], but the in vitro functional
study of the p.P359S-p.N662S MAMLD1 variant was inconclusive
with unchanged transactivation function [13]. In the present
study, we show that the combination of these alleles was present in
as much as 15% of patients with severe 46,XY DSD. This is
significantly higher than in the controls [combining the series,
15% (n=70) vs. 10.7% (n=510), p=0.0003]. Again, a transient
testosterone production failure during prenatal development may
have contributed to the undervirilization of the external genitalia,
but how this haplotype can be present in normal, mild and severe
phenotypes remains to be elucidated.
Severe undervirilization in XY newborns can reveal mutations
of MAMLD1. MAMLD1 should be routinely sequenced in these
patients with otherwise normal AR, SRD5A2 and NR5A1 genes.
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